;PMID: 7772432
;source_file_904.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..36] = [t:0..36]
;1)sentence:[e:42..112] = [t:42..112]
;2)section:[e:116..166] = [t:116..166]
;3)section:[e:170..264] = [t:170..264]
;4)sentence:[e:268..547] = [t:268..547]
;5)sentence:[e:548..704] = [t:548..704]
;6)sentence:[e:705..878] = [t:705..878]
;7)sentence:[e:879..1015] = [t:879..1015]
;8)sentence:[e:1016..1122] = [t:1016..1122]
;9)sentence:[e:1123..1252] = [t:1123..1252]
;10)sentence:[e:1253..1443] = [t:1253..1443]
;11)section:[e:1447..1491] = [t:1447..1490]
;Sentence Matching Errors
;ERROR_Section end mismatch[e:1447..1491][t:1447..1490]
;Token/POS Errors
;ERROR_Token in entity file but not tree[1490..1491] ]

;section 0 Span:0..36
;Br J Anaesth. 1995 May;74(5):558-62.
(SEC
  (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..12] Anaesth) (.:[12..13] .)
        (CD:[14..18] 1995) (NNP:[19..22] May) (::[22..23] ;) (CD:[23..25] 74)
        (-LRB-:[25..26] -LRB-) (CD:[26..27] 5) (-RRB-:[27..28] -RRB-)
        (::[28..29] :) (CD:[29..32] 558) (::[32..33] -) (CD:[33..35] 62)
        (.:[35..36] .)))

;sentence 1 Span:42..112
;Human cytochrome P450 mono-oxygenase system is suppressed by propofol.
;[48..78]:substance:"cytochrome P450 mono-oxygenase"
;[103..111]:substance:"propofol"
(SENT
  (S-HLN
    (NP-SBJ-1 (JJ:[42..47] Human)
      
      (NML (NN:[48..58] cytochrome) (NN:[59..63] P450))
      (NN:[64..78] mono-oxygenase)
      (NN:[79..85] system))
    (VP (VBZ:[86..88] is)
      (VP (VBN:[89..99] suppressed)
        (NP-1 (-NONE-:[99..99] *))
        (PP (IN:[100..102] by)
          (NP-LGS (NN:[103..111] propofol)))))
    (.:[111..112] .)))

;section 2 Span:116..166
;Chen TL, Ueng TH, Chen SH, Lee PH, Fan SZ, Liu CC.
(SEC
  (FRAG (NNP:[116..120] Chen) (NNP:[121..123] TL) (,:[123..124] ,)
        (NNP:[125..129] Ueng) (NNP:[130..132] TH) (,:[132..133] ,)
        (NNP:[134..138] Chen) (NNP:[139..141] SH) (,:[141..142] ,)
        (NNP:[143..146] Lee) (NNP:[147..149] PH) (,:[149..150] ,)
        (NNP:[151..154] Fan) (NNP:[155..157] SZ) (,:[157..158] ,)
        (NNP:[159..162] Liu) (NNP:[163..166] CC.)))

;section 3 Span:170..264
;Department of Anesthesiology, National Taiwan University Hospital, Taipei, 
;Republic of China.
(SEC
  (FRAG (NNP:[170..180] Department) (IN:[181..183] of)
        (NNP:[184..198] Anesthesiology) (,:[198..199] ,)
        (NNP:[200..208] National) (NNP:[209..215] Taiwan)
        (NNP:[216..226] University) (NNP:[227..235] Hospital) (,:[235..236] ,)
        (NNP:[237..243] Taipei) (,:[243..244] ,) (NNP:[246..254] Republic)
        (IN:[255..257] of) (NNP:[258..263] China) (.:[263..264] .)))

;sentence 4 Span:268..547
;We have studied the effect of propofol on the cytochrome P450-dependent 
;mono-oxygenase system in human liver microsomes by assaying mono-oxygenase 
;activities toward specific cytochrome P450 isoform test substrates, aniline, 
;7-ethoxycoumarin, benzphetamine and benzo(a) pyrene.
;[298..306]:substance:"propofol"
;[314..355]:substance:"cytochrome P450-dependent  mono-oxygenase"
;[401..415]:substance:"mono-oxygenase"
;[444..467]:cyp450:"cytochrome P450 isoform"
;[473..483]:substance:"substrates"
;[485..492]:substance:"aniline"
;[495..511]:substance:"7-ethoxycoumarin"
;[513..526]:substance:"benzphetamine"
;[531..546]:substance:"benzo(a) pyrene"
(SENT
  (S
    (NP-SBJ (PRP:[268..270] We))
    (VP (VBP:[271..275] have)
      (VP (VBN:[276..283] studied)
        (NP
          (NP (DT:[284..287] the) (NN:[288..294] effect))
          (PP (IN:[295..297] of)
            (NP (NN:[298..306] propofol)))
          (PP (IN:[307..309] on)
            (NP (DT:[310..313] the)
              
              (ADJP
                (NML (NN:[314..324] cytochrome) (NN:[325..329] P450))
                (HYPH:[329..330] -) (JJ:[330..339] dependent))
              (NN:[341..355] mono-oxygenase)
              (NN:[356..362] system))))
        (PP-LOC (IN:[363..365] in)
          (NP (JJ:[366..371] human) (NN:[372..377] liver)
              (NNS:[378..388] microsomes)))
        (PP-MNR (IN:[389..391] by)
          (S-NOM
            (NP-SBJ (-NONE-:[391..391] *))
            (VP (VBG:[392..400] assaying)
              (NP (NN:[401..415] mono-oxygenase) (NNS:[417..427] activities))
              (PP (IN:[428..434] toward)
                (NP
                  (NP (JJ:[435..443] specific)
                    
                    (NML (NN:[444..454] cytochrome) (NN:[455..459] P450))
                    (NN:[460..467] isoform)
                    (NN:[468..472] test) (NNS:[473..483] substrates))
                  (,:[483..484] ,)
                  (NP
                    (NP (NN:[485..492] aniline))
                    (,:[492..493] ,)
                    (NP (NN:[495..511] 7-ethoxycoumarin))
                    (,:[511..512] ,)
                    (NP (NN:[513..526] benzphetamine))
                    (CC:[527..530] and)
                    (NP (NN:[531..539] benzo-LRB-a-RRB-) (NN:[540..546] pyrene))))))))))
    (.:[546..547] .)))

;sentence 5 Span:548..704
;Propofol inhibited  benzo(a)pyrene hydroxylation to a greater extent than the
;oxidative metabolism  of the other test substrates, even at 0.05 mmol
;litre-1.
;[548..556]:substance:"Propofol"
;[568..582]:substance:"benzo(a)pyrene"
;[666..676]:substance:"substrates"
;[686..690]:quantitative-value:"0.05"
;[691..703]:quantitative-units:"mmol litre-1"
(SENT
  (S
    (NP-SBJ (NN:[548..556] Propofol))
    (VP (VBD:[557..566] inhibited)
      (NP (NN:[568..582] benzo-LRB-a-RRB-pyrene) (NN:[583..596] hydroxylation))
      (PP (TO:[597..599] to)
        (NP
          (NP (DT:[600..601] a) (JJR:[602..609] greater) (NN:[610..616] extent))
          (PP (IN:[617..621] than)
            (NP
              (NP (DT:[622..625] the) (JJ:[626..635] oxidative)
                  (NN:[636..646] metabolism))
              (PP (IN:[648..650] of)
                (NP (DT:[651..654] the) (JJ:[655..660] other)
                    (NN:[661..665] test) (NNS:[666..676] substrates)))))))
      (,:[676..677] ,)
      (PP
        (ADVP (RB:[678..682] even))
        (IN:[683..685] at)
        (NP
          (NML (CD:[686..690] 0.05) (NN:[691..695] mmol))
          (NN:[696..703] litre-1))))
    (.:[703..704] .)))

;sentence 6 Span:705..878
;The degrees of  inhibition of benzphetamine N-demethylation and
;7-ethoxy-coumarin  O-de-ethylation were similar, while aniline hydroxylation
;was least affected by  propofol.
;[735..748]:substance:"benzphetamine"
;[769..786]:substance:"7-ethoxy-coumarin"
;[824..831]:substance:"aniline"
;[869..877]:substance:"propofol"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[705..708] The) (NNS:[709..716] degrees))
      (PP (IN:[717..719] of)
        (NP
          (NP (NN:[721..731] inhibition))
          (PP (IN:[732..734] of)
            (NP
              (NP (NN:[735..748] benzphetamine) (NN:[749..750] N)
                  (HYPH:[750..751] -) (NN:[751..764] demethylation))
              (CC:[765..768] and)
              (NP (NN:[769..786] 7-ethoxy-coumarin) (NN:[788..789] O)
                  (HYPH:[789..790] -) (NN:[790..803] de-ethylation)))))))
    (VP (VBD:[804..808] were)
      (ADJP-PRD (JJ:[809..816] similar))
      (,:[816..817] ,)
      (SBAR-ADV (IN:[818..823] while)
        (S
          (NP-SBJ-1 (NN:[824..831] aniline) (NN:[832..845] hydroxylation))
          (VP (VBD:[846..849] was)
            (ADVP (RBS:[850..855] least))
            (VP (VBN:[856..864] affected)
              (NP-1 (-NONE-:[864..864] *))
              (PP (IN:[865..867] by)
                (NP-LGS (NN:[869..877] propofol))))))))
    (.:[877..878] .)))

;sentence 7 Span:879..1015
;Spectral analysis showed that propofol competed with carbon monoxide  for
;binding to the haem moiety of haemoprotein in the P450 enzyme.
;[909..917]:substance:"propofol"
;[932..947]:substance:"carbon monoxide"
;[968..972]:substance:"haem"
;[983..995]:substance:"haemoprotein"
;[1003..1014]:cyp450:"P450 enzyme"
(SENT
  (S
    (NP-SBJ (JJ:[879..887] Spectral) (NN:[888..896] analysis))
    (VP (VBD:[897..903] showed)
      (SBAR (IN:[904..908] that)
        (S
          (NP-SBJ (NN:[909..917] propofol))
          (VP (VBD:[918..926] competed)
            (PP (IN:[927..931] with)
              (NP (NN:[932..938] carbon) (NN:[939..947] monoxide)))
            (PP (IN:[949..952] for)
              (S-NOM
                (NP-SBJ (-NONE-:[952..952] *))
                (VP (VBG:[953..960] binding)
                  (PP (TO:[961..963] to)
                    (NP
                      (NP (DT:[964..967] the) (NN:[968..972] haem)
                          (NN:[973..979] moiety))
                      (PP (IN:[980..982] of)
                        (NP (NN:[983..995] haemoprotein))))))))
            (PP (IN:[996..998] in)
              (NP (DT:[999..1002] the)
                 (NN:[1003..1007] P450) (NN:[1008..1014] enzyme)))))))
    (.:[1014..1015] .)))

;sentence 8 Span:1016..1122
;The variable  inhibition observed may be caused by the differential binding
;of propofol to  P450 isoforms.
;[1095..1103]:substance:"propofol"
;[1108..1121]:cyp450:"P450 isoforms"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1016..1019] The) (JJ:[1020..1028] variable)
          (NN:[1030..1040] inhibition))
      (VP (VBN:[1041..1049] observed)
        (NP (-NONE-:[1049..1049] *))))
    (VP (MD:[1050..1053] may)
      (VP (VB:[1054..1056] be)
        (VP (VBN:[1057..1063] caused)
          (NP-1 (-NONE-:[1063..1063] *))
          (PP (IN:[1064..1066] by)
            (NP-LGS
              (NP (DT:[1067..1070] the) (JJ:[1071..1083] differential)
                  (NN:[1084..1091] binding))
              (PP (IN:[1092..1094] of)
                (NP (NN:[1095..1103] propofol)))
              (PP (TO:[1104..1106] to)
                (NP (NN:[1108..1112] P450) (NNS:[1113..1121] isoforms))))))))
    (.:[1121..1122] .)))

;sentence 9 Span:1123..1252
;Propofol 0.05-1.0 mmol litre-1 exhibited a  concentration-dependent
;inhibitory effect on human cytochrome P450 2E1, 2B1 and  1A1.
;[1123..1131]:substance:"Propofol"
;[1132..1140]:quantitative-value:"0.05-1.0"
;[1141..1153]:quantitative-units:"mmol litre-1"
;[1218..1237]:cyp450:"cytochrome P450 2E1"
;[1218..1233]...[1248..1251]:cyp450:"cytochrome P450"..."1A1"
;[1218..1233]...[1239..1242]:cyp450:"cytochrome P450"..."2B1"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1123..1131] Propofol))
      (NP
        (NML
          (QP (CD:[1132..1136] 0.05) (HYPH:[1136..1137] -) (CD:[1137..1140] 1.0))
          (NN:[1141..1145] mmol))
        (NN:[1146..1153] litre-1)))
    (VP (VBD:[1154..1163] exhibited)
      (NP (DT:[1164..1165] a)
        (ADJP (NN:[1167..1180] concentration) (HYPH:[1180..1181] -)
              (JJ:[1181..1190] dependent))
        (JJ:[1191..1201] inhibitory) (NN:[1202..1208] effect))
      (PP (IN:[1209..1211] on)
        (NP
          (NP
            (ADJP-2 (JJ:[1212..1217] human))
            
            (NML-1 (NN:[1218..1228] cytochrome) (NN:[1229..1233] P450))
            (NN:[1234..1237] 2E1))
          (,:[1237..1238] ,)
          (NP
            (ADJP-2 (-NONE-:[1238..1238] *P*))
            (NML-1 (-NONE-:[1238..1238] *P*))
            (NN:[1239..1242] 2B1))
          (CC:[1243..1246] and)
          (NP
            (ADJP-2 (-NONE-:[1246..1246] *P*))
            (NML-1 (-NONE-:[1246..1246] *P*))
            (NN:[1248..1251] 1A1)))))
    (.:[1251..1252] .)))

;sentence 10 Span:1253..1443
;These inhibitory actions of propofol on human liver microsomal enzymes in 
;vitro suggest that potential drug interactions may exist between propofol and
; other drugs administered clinically.
;[1281..1289]:substance:"propofol"
;[1316..1323]:substance:"enzymes"
;[1357..1361]:substance:"drug"
;[1393..1401]:substance:"propofol"
;[1413..1418]:substance:"drugs"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1253..1258] These) (JJ:[1259..1269] inhibitory)
          (NNS:[1270..1277] actions))
      (PP (IN:[1278..1280] of)
        (NP (NN:[1281..1289] propofol)))
      (PP (IN:[1290..1292] on)
        (NP (JJ:[1293..1298] human) (NN:[1299..1304] liver)
            (JJ:[1305..1315] microsomal) (NNS:[1316..1323] enzymes)))
      (ADVP (FW:[1324..1326] in) (FW:[1328..1333] vitro)))
    (VP (VBP:[1334..1341] suggest)
      (SBAR (IN:[1342..1346] that)
        (S
          (NP-SBJ
            (NP (JJ:[1347..1356] potential) (NN:[1357..1361] drug)
                (NNS:[1362..1374] interactions))
            (PP-1 (-NONE-:[1374..1374] *ICH*)))
          (VP (MD:[1375..1378] may)
            (VP (VB:[1379..1384] exist)
              (PP-1 (IN:[1385..1392] between)
                (NP
                  (NP (NN:[1393..1401] propofol))
                  (CC:[1402..1405] and)
                  (NP
                    (NP (JJ:[1407..1412] other) (NNS:[1413..1418] drugs))
                    (VP (VBN:[1419..1431] administered)
                      (NP (-NONE-:[1431..1431] *))
                      (ADVP (RB:[1432..1442] clinically)))))))))))
    (.:[1442..1443] .)))

;section 11 Span:1447..1490
;PMID: 7772432 [PubMed - indexed for MEDLINE
(SEC
  (FRAG (NNP:[1447..1451] PMID) (::[1451..1452] :) (CD:[1453..1460] 7772432)
        (-LRB-:[1461..1462] -LSB-) (NNP:[1462..1468] PubMed) (::[1469..1470] -)
        (VBN:[1471..1478] indexed) (IN:[1479..1482] for)
        (NNP:[1483..1490] MEDLINE)))
;ERROR_Orphan Text from EOF Tree File[1490..EOF] ]

(ORPH -RSB-)
